AstraZeneca Pharma India enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
15,593————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
448448536506500
15,145————
−448−448−536−506−500
₹6,057.91————
873873770712589
6.23×————
65.89×————
71.23×————
Reference items — trailing FY values
2,4322,2761,7161,2961,003
230262254184165
213233214170149
—−15.165.492.558.3
−18.8−18.863.681.849.8
—−19.963.681.649.6
—3.61.810.88.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ASTRAZEN₹6,237.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹15,593 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————15,592.5
- Cash, Equiv & ST Investments500.3505.6536.1447.7447.7
Enterprise Value————15,144.8
Net Debt (memo)-500.3-505.6-536.1-447.7-447.7
EV per Share————6,057.91
Total Capital588.7711.9770.4872.8872.8
EV/Sales————6.23
EV/EBITDA————65.89
EV/EBIT————71.23
Reference Items — Trailing FY Values
Sales1,003.01,295.51,716.32,275.62,432.1
EBITDA165.1184.4254.0262.0229.9
EBIT148.9169.5214.0233.5212.6
Operating Cash Flow58.392.565.4-15.1—
Free Cash Flow49.881.863.6-18.8-18.8
FCFF (free cash flow to the firm)49.681.663.6-19.9—
Capital Expenditure8.510.81.83.6—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.